Toxicity of bisphosphonates

Journal of Palliative Medicine

Volumn 12, Issue 11, 2009, Pages 1061-1065

  Prommer, Eric E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE; CLODRONIC ACID; CORTICOSTEROID; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; IBANDRONIC ACID; PAMIDRONIC ACID; VINCRISTINE SULFATE; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; ANEMIA; ARTHRALGIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACKACHE; BONE METASTASIS; BONE PAIN; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CONJUNCTIVITIS; CONVALESCENCE; DIALYSIS; DRUG WITHDRAWAL; EYE PAIN; FATIGUE; FEVER; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG CANCER; MALE; MORBIDITY; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEPHROTIC SYNDROME; NOTE; PAIN; PRACTICE GUIDELINE; PROSTATE CANCER; RECURRENT CANCER; SCLERITIS; SOLID TUMOR; UVEITIS;

DIPHOSPHONATES; ECONOMICS, PHARMACEUTICAL; HUMANS; JAW; MALE; MIDDLE AGED; OSTEONECROSIS; PALLIATIVE CARE;

EID: 70450206020     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2009.9936     Document Type: Note

References (29)

1. Woo SB, Hellstein JW, Kalmar JR: Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761.
2. von Moos R, Strasser F, Gillessen S, Zaugg K: Metastatic bone pain: Treatment options with an emphasis on bisphosphonates. Support Care Cancer 2008;16:1105-1115.
3. Sabino MA, Mantyh PW: Pathophysiology of bone cancer pain. J Support Oncol 2005;3:15-24.
4. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, PapadimitriouC, Terpos E,DimopoulosMA: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
5. Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M: International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007;43:852-858. (Pubitemid 46366687)
6. Lin JH: Bisphosphonates: A review of their pharmacokinetic properties. Bone 1996;18:75-85.
7. Senel FC, Saracoglu TU, Durmus A, Bagis B: Severe osteomyelitis of the mandible associated with the use of nonnitrogen-containing bisphosphonate (disodium clodronate): Report of a case. J Oral Maxillofac Surg 2007;65:562-565.
8. Yeh HS, Berenson JR: Treatment for myeloma bone disease. Clin Cancer Res 2006;12:6279s-66284.
9. Clarke BM, Boyette J, Vural E, Suen JY, Anaissie EJ, Stack BC Jr: Bisphosphonates and jaw osteonecrosis: The UAMS experience. Otolaryngol Head Neck Surg 2007;136:396-400.
10. Bertoldo F, Santini D, Lo Cascio V: Bisphosphonates and osteomyelitis of the jaw: A pathogenic puzzle. Nat Clin Pract Oncol 2007;4:711-721.
11. Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, Fornier M, Halpern JL, Tunick SJ, Huryn JM: Osteonecrosis of the maxilla and mandible in Patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008;13:911-920.
12. Sciubba JJ, Goldenberg D: Oral complications of radiotherapy. Lancet Oncol 2006;7:175-183.
13. Jackson GH: Renal safety of ibandronate. Oncologist 2005;10(Suppl 1):14-18.
14. Diel IJ, Bergner R, Grotz KA: Adverse effects of bisphosphonates: Current issues. J Support Oncol 2007;5:475-482.
15. Chang JT, Green L, Beitz J: Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-1679.
16. Tanvetyanon T, Stiff PJ: Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907.
17. Berenson JR, Vescio RA, Rosen LS, VonTeichert JM, Woo M, Swift R, Savage A, Givant E, Hupkes M, Harvey H, Lipton A: A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001;7:478-485.
18. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD: Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-289.
19. Markowitz GS, Fine PL, D'Agati VD: Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 2002;39: 1118-1122.
20. Desikan R, Veksler Y, Raza S, Stokes B, Sabir T, Li ZJ, Jagannath S: Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 2002;119: 496-499.
21. Bergner R, Diel IJ, Henrich D, Hoffmann M, Uppenkamp M: Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 2006;29:534-540.
22. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Cancer Study Group: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
23. Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R, Tonini G: Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 2003;23: 649-654.
24. Fraunfelder FW, Fraunfelder FT: Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 2004;111: 1275-1279.
25. Moore MM, Beith JM: Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer. Med J Aust 2008;188:370-371.
26. ZOMETA-IV injection, zoledronic acid IV injection [product information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2008.
27. AREDIA-IV injection, pamidronate disodium IV injection [product information]. East Hanover, NJ: Novartis, 2008.
28. Devitt B, McLachlan SA: Use of ibandronate in the prevention of skeletal events in metastatic breast cancer. Ther Clin Risk Manag 2008;4:453-458.
29. Epocrates Online: www.epocrates.com (Last accessed September 25, 2009).